Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.

Gumus, MahmutChen, Chieh-IIvanescu, CristinaKilickap, SaadettinBondarenko, IgorOzguroglu, MustafaGogishvili, Miranda2024-06-122024-06-1220210732-183X1527-7755https://doi.org/10.1200/JCO.2021.39.15_suppl.9078https://hdl.handle.net/20.500.14551/25941Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORK[Abstract Not Available]en10.1200/JCO.2021.39.15_suppl.9078info:eu-repo/semantics/closedAccess[No Keywords]Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.Conference Object3915Q1WOS:000708120605058